Just riding my bicycle.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cassava up on DSMB review.
Humacyte up today on genuinely positive SA piece.
https://seekingalpha.com/article/4722917-humacyte-navigating-the-fda-uncertainty-and-atevs-potential
Coya announces that CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will participate in a fireside chat at the Chardan 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:00pm ET.
Amazon Pharmacy ships. My prescription refills come reliably and at a competitive price.
Isn't it weird how those big MOC trades are priced near the VWAP.
Why would the FDA provide a trial review? Anavex hasn't even filed an IND.
re. "2009 column 2-73 Alzheimer's IND"
Have they ever even filed the IND?
re. "relapsed/refractory micro-satellite stable colorectal cancer (“CRC")"
What is the prior research backing this clinical indication? Seems out of the blue to me.
Hey you're out! How does that sun feel?
re: "The gut-brain axis".
Here we have research which finds an actual relationship: Upper GI mucosal damage and Parkinsons.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823250
You're implying that FSD is based entirely on GPS. You are entirely incorrect.
Rarely do I see pre-market volume. 2K so far today. Nice.
My take on FDA delay: FDA wants to see full details concerning the following sentence:
re. "the difference was in the dosages examined in Part A"
So Part A ran all the 30mg and now they're running all the 60mg? What next? All the placebos?
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Expands-Pipeline-and-Intellectual-Property-Portfolio-with-Filing-of-New-U.S.-Patents-for-COYA-301-in-Combination-with-Glucagon-Like-Peptide-1-GLP-1-Receptor-Agonists/default.aspx
COYA to present AD results at CTAD24
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-that-Results-from-a-Double-Blind-Placebo-Controlled-Study-in-Alzheimers-Disease-will-be-presented-on-October-29-2024-at-the-Clinical-Trials-on-Alzheimers-Disease-Conference-CTAD24-in-Madrid/default.aspx
Truly good news! This establishes a pattern of new applications.
Thank You Janice! Amit has sprung from Non-Existent posting history, so I was wondering.
The original ethe is now divided into new AMEX:ethe (trust) + AMEX:eth (etf). Not whatever this NYSE shit is.
Sitrick And Company is Cassava's new PR firm. What do you think about that?
Wow! Just saw. What's missing is the motive.
We are left with guessing and that's not a good place to be.
I'm out. Been out.
I haven't posted in a while. Waiting for results.
Coya 8K July 15
On June 14, 2024, Coya Therapeutics, Inc. (the “Company”) submitted to the U.S. Food and Drug Administration (the “FDA”) an Investigational New Drug Application (the “IND”) seeking to initiate a study entitled “Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Open Label Extension (OLE) to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)” (the “Study”). On July 12, 2024, the Company received an email notification from the FDA stating that additional non-clinical data is required prior to the initiation of the Study. The FDA also stated that it would provide the Company with more details about what additional information it requires within the next thirty (30) days.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524178809/d762748d8k.htm
Why would Cytodyn announce a pre-clinical study for MASH?
The FDA Has Approved a New Treatment for a Liver Disease Called MASH (Metabolic Dysfunction-Associated Steatohepatitis)
NEW YORK , June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS).
I know my previous post was a bit mysterious but perhaps the following video will help to clarify.
Filamin-A is a scaffolding protein. Here is page 13 from the latest Cassava corp presentation.
Do you see that Destabilized Microtibule? That may be playing a role in ALZ.
The relationship was first conjectured by Roger Penrose (physicist) and Stuart Hameroff (anesthesiologist) .
Recently this conjecture has advanced to become a hypothesis
Read all about it 10am EDT
https://www.sec.gov/Archives/edgar/data/1314052/000173112224000730/e5638_def14a.htm
What going on with $HUMA? Well, I'll tell ya.
(1) New Diagnostic/Billing Codes
(2) Director Unloads 10%
(3) Yawn, Tuberville sold HUMA
Anecdotal observation of MCD. Order a shake or McFlurry. The machines are broken. And I mean broken for months.
LOL. You'll have to ask his accounting man.
$COYA ALS Peer-Reviewed Publication:
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1415106/full
Dang MsPoopyHead.
You should meet MrHankey
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology. A portion of the data from the manuscript was previously presented at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference.
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93970259/coya-therapeutics-announces-acceptance-of-peer-rev
Today 2 Jun is #LouGehrigDay #EndALS
Yeah Yahoo doesn't want you clicking off-site. They lose ad revenue.
Anyone placing huge market sell orders like that is a f**king moron.